{"TopicDetails": {"type": 0, "ccm2Id": 31100157, "cftId": 0, "identifier": "IMI2-2018-15-04", "title": "Emerging translational safety technologies and tools for interrogating human immuno-biology", "publicationDateLong": 1531872000000, "callIdentifier": "H2020-JTI-IMI2-2018-15-two-stage", "callTitle": "H2020-JTI-IMI2-2018-15-two-stage", "callccm2Id": 31100164, "allowPartnerSearch": true, "workProgrammepart": {"id": 267551, "ccm_id": 31095847, "wp_part": "H2020-JTI-IMI-2018", "wp_year": "H2020-JTI-IMI-2018", "wp_title": "H2020-JTI-IMI-2018", "wp_website": "http://www.imi.europa.eu/", "wp_document": "http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp18-imi2_en.pdf"}, "frameworkProgramme": {"id": 31045243, "abbreviation": "H2020", "description": "Horizon 2020 Framework Programme"}, "programmeDivision": [{"id": 31047894, "abbreviation": "EU.3.1.", "description": "Health, demographic change and wellbeing"}, {"id": 31047893, "abbreviation": "EU.3.", "description": "Societal Challenges"}, {"id": 31062059, "abbreviation": "EU.3.1.7.", "description": "Innovative Medicines Initiative 2 (IMI2)"}, {"id": 31045244, "abbreviation": "EC", "description": "EC Treaty"}], "topicMGAs": [], "tags": ["immuno-biology", "IMI2-2018-15-04", "H2020-JTI-IMI2-2018-15-two-stage", "IMI2", "IMI2 JU", "cytokine release syndrome", "immuno-inflammatory disease", "Innovative Medicines Initiative", "Joint Undertaking", "drug development", "Emerging translational safety technologies and tools for interrogating human immuno-biology", "immuno-oncology", "translational safety technologies"], "keywords": ["Translational medicine", "Suppression immunotherapies", "Biomarkers", "Activation immunotherapies", "Immunology"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "IMI2-RIA Research and Innovation action", "typeOfMGA": []}], "plannedOpeningDate": "18 July 2018", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["24 October 2018", "15 May 2019"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3272690": [{"action": "IMI2-2018-15-03 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-02 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-01 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-08 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-07 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-04 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-05 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-06 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2018"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p>For full details of the topic, please see the call text on the IMI website.</p><p>There is an urgent need to better understand inherent risks of innovative therapeutics for immuno-oncology and immuno-inflammatory disease indications including cytokine release syndrome, infection, malignancy and autoimmunity during early (non-clinical) stages of drug development. The toxicities induced by immunomodulatory therapeutics in patients are often not detected in the young healthy animal models that are routinely used for toxicology studies either due the lack of expression of appropriate drug targets/pathways or due to differences in drug target genetics, expression and functions between animal models and the intended patient populations. Thus, innovative translational safety assessment tools, technologies, models and resources are needed to facilitate the development of novel immunomodulatory drugs (either immunostimulatory or immunosuppressive).</p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>For full details of the topic, please see the call text on the IMI website.</p><p>This topic aims to establish a public-private consortium that will enhance translational safety assessment approaches for immunomodulatory therapeutics (spanning oncology and non-oncology indications), with an emphasis on evaluating human-relevance.</p><p>The following objectives are within the scope of this proposal:</p><ol level=\"0\">  <li>development of innovative comparative (cross-species) in situ and ex vivo molecular, biochemical tools and cellular profiling of immune cells (including patient-derived clinical samples) and association with functional/phenotypic endpoints to enable;<br></li><li>establishment, refinement and validation of non-clinical tools and models to enable the development of novel classes of immunomodulatory medicines supporting in vitro-in vivo and cross-species translation.</li> </ol>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p>For full details of the topic, please see the call text on the IMI website.</p><p>The action generated by this topic will ultimately help deliver safer medicines to patients via:</p><ul level=\"0\"><li>provision of new tools and models to enable a better understanding of the inherent safety risks of immunomodulatory therapeutics;</li><li>improvement of drug development processes and regulatory assessments for immunomodulatory therapeutics;</li><li>better definition of limitations in the translatability of non-clinical test systems to patients and will also contribute to the principles of the 3Rs.</li> </ul><p>Small and medium-sized enterprises (SMEs) can be of great benefit to IMI2 JU projects. Their involvement in the action might offer a complementary perspective to industry and academia, and help deliver the long-term impact of the action.</p>\n", "conditions": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Please read carefully all provisions stated below before the preparation of your application.<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">The IMI2 JU 15th Call for proposals topics text as well as the Call Conditions are available </span></b><b><u><span style=\"font-size:9.0pt;font-family:&#10;&quot;Arial&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;;color:blue;&#10;mso-fareast-language:EN-GB\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche18-15-imi2-ju_en.pdf\" target=\"_blank\">here</a></span></u></b><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">.&nbsp;&nbsp;</span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">The budget breakdown for this Call is given at the end of the Call topics text, in the </span></b><b><u><span style=\"font-size:9.0pt;font-family:&#10;&quot;Arial&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;;color:blue;&#10;mso-fareast-language:EN-GB\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche18-15-imi2-ju_en.pdf\" target=\"_blank\">Call Conditions</a></span></u></b><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> section, as well as the following information :&nbsp;</span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>1.&nbsp;&nbsp; Eligible countries:</strong></span> described in article 10(2) of the <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Rules for participation in  Horizon 2020</a> and in article 1 of the <a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>2.&nbsp;&nbsp; Eligibility and admissibility conditions:</strong></span> described in the <strong><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.6_en.pdf\" target=\"_blank\">IMI2 Manual for evaluation, submission and grant award</a>.</strong>  See also the <a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Proposal page limits and layout:</strong></span> Please refer to Part B of the proposal template in the submission tool below.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>3.&nbsp;&nbsp; Evaluation: </strong></span><br />\r\nSubmission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the <strong><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.6_en.pdf\" target=\"_blank\">IMI2 Manual for submission, evaluation and grant award</a></strong>. See also the proposal templates for your specific action in section 5, below.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>4.&nbsp;&nbsp; Indicative time for evaluation and grant agreement: </strong></span><br />\r\nNotification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.<br />\r\nNotification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.</p>\r\n<p>Signature of grant agreements: maximum 3 months from the date of informing successful applicants.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>5.&nbsp;&nbsp; Proposal templates, evaluation forms and model grant agreements (MGA):</strong></span></p>\r\n<p><strong>IMI2 Research and Innovation Action (IMI2-RIA) </strong><strong>and Innovation Action (IMI2-IA):</strong></p>\r\n<p>Proposal templates are available after entering the submission tool<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/ef/h2020-call-ef-imi2-ria-ia-2016_en.pdf\" target=\"_blank\"><br />\r\nStandard evaluation form</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-mga-imi_en.pdf\" target=\"_blank\">IMI2 Model Grant Agreement</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/legal/templ/h2020_tmpl-clinical-studies_2018-2020_en.pdf \" target=\"_blank\">Clinical trial template</a>&nbsp;&ndash; the Clinical Trial template is compulsory at stage 2 only !</p>\r\n<p>&nbsp;</p>\n<p><strong><span style=\"color: rgb(0, 51, 102);\">6.&nbsp;&nbsp; Open access must be granted to all scientific publications </span></strong>resulting from Horizon 2020 actions.</p>\r\n<p>Where relevant, proposals should also provide information on how the  participants will manage the research data generated and/or collected  during the project, such as details on what types of data the project  will generate, whether and how this data will be exploited or made  accessible for verification and re-use, and how it will be curated and  preserved.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Open access to research data</strong></span><br />\r\nThe Open Research Data Pilot has been extended to cover all Horizon 2020  topics for which the submission is opened on 26 July 2016 or later.  Projects funded under this topic will therefore by default provide open  access to the research data they generate, except if they decide to  opt-out under the conditions described in <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-l-openaccess_en.pdf\" target=\"_blank\">Annex L of the H2020 main Work Programme</a>. Projects can opt-out at any stage, that is both before and after the grant signature.</p>\r\n<p>Note that the evaluation phase proposals will not be evaluated more  favourably because they plan to open or share their data, and will not  be penalised for opting out.</p>\r\n<p>Open research data sharing applies to the data needed to validate the  results presented in scientific publications. Additionally, projects  can choose to make other data available open access and need to describe  their approach in a Data Management Plan.</p>\r\n<p>Projects need to create a Data Management Plan (DMP), except if they  opt-out of making their research data open access. A first version of  the DMP must be provided as an early deliverable within six months of  the project and should be updated during the project as appropriate. The  Commission already provides guidance documents, including a template  for DMPs. See the <a href=\"https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/open-access-dissemination_en.htm\" target=\"_blank\">Online Manual</a>.</p>\r\n<p>Eligibility of costs: costs related to data management and data  sharing are eligible for reimbursement during the project duration.</p>\r\n<p>The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.&nbsp;</p>\n<p>Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>7. Additional documents:</strong></span></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-rel-prov-imi-ju_en.pdf\" target=\"_blank\">Summary of the most relevant provisions for participating in IMI2 actions</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp18-imi2-amend-3_en.pdf\" target=\"_blank\">3rd Amended IMI2 Annual Work Plan 2018<br />\r\n</a><br />\r\n<a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/apply-for-funding/call-documents/imi2/RegulatoryRequirementsGuide.pdf\" target=\"_blank\">IMI2 Regulators Guidance tool for researchers</a></p>\r\n<p><a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:JOL_2014_174_R_0003\" target=\"_blank\">IMI JU derogation to H2020 Rules for Participation</a> &nbsp;<br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Horizon 2020 Rules for Participation&nbsp;</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/fp/h2020-eu-establact_en.pdf\" target=\"_blank\">Horizon 2020 Regulation of Establishment <br />\r\n</a><br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/sp/h2020-sp_en.pdf\" target=\"_blank\">Horizon 2020 Specific Programme</a></p>\r\n<p>&nbsp;</p>", "supportInfo": "<p><span style=\"color: rgb(0, 51, 102);\"><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/index_en.htm\" target=\"_blank\"><strong>H2020 Online Manual</strong></a> </span>is your guide on the procedures from proposal submission to managing your grant.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/portal/desktop/en/support/faq.html#c,faqs=categoryMachineName/t/pp_roles_and_rights/0/1/1/category&amp;categoryMachineName/t/p_registration/0/1/1/category&amp;categoryMachineName/t/work_programme_calls/0/1/1/category&amp;categoryMachineName/t/p_submission_eval/1/1/1/category&amp;categoryMachineName/t/ethics_research_integrity/0/1/1/category&amp;categoryMachineName/t/grants/0/1/1/category&amp;categoryMachineName/t/audit/0/1/1/category&amp;categoryMachineName/t/experts/0/1/1/category&amp;categoryMachineName/t/eu_research_policy/0/1/1/category&amp;programmeList/t/H2020/0/1/1/programme&amp;programmeList/t/3rd_health_programme/0/1/1/programme&amp;programmeList/t/asylum_migration_and_integration_fund/0/1/1/programme&amp;programmeList/t/consumer_programme/0/1/1/programme&amp;programmeList/t/COSME/0/1/1/programme&amp;programmeList/t/creative_europe_programme/0/1/1/programme&amp;programmeList/t/erasmus_programme/0/1/1/programme&amp;programmeList/t/FP7/0/1/1/programme&amp;programmeList/t/hercule_iii_programme/0/1/1/programme&amp;programmeList/t/internal_security_fund_borders/0/1/1/programme&amp;programmeList/t/internal_security_fund_police/0/1/1/programme&amp;programmeList/t/justice_programme/0/1/1/programme&amp;programmeList/t/pilot_projects_preparatory_actions/0/1/1/programme&amp;programmeList/t/promotion_of_agricultural_products/0/1/1/programme&amp;programmeList/t/research_fund_for_coal_and_steel/0/1/1/programme&amp;programmeList/t/rights_equality_and_citizenship_programme/0/1/1/programme&amp;programmeList/t/union_civil_protection_mechanism/0/1/1/programme&amp;programmeList/t/european_statistics/0/1/1/programme&amp;tagList/t/MSCA/0/1/1/tag&amp;tagList/t/ERC/0/1/1/tag\" target=\"_blank\"><strong><span style=\"color: rgb(0, 51, 102);\">Participant Portal FAQ</span></strong></a> &ndash; Submission of proposals.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/portal4/desktop/en/support/national_contact_points.html\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>National Contact Points (NCP)</strong></span></a> - contact your NCP for further assistance in your national language(s).</p>\r\n<p><a href=\"http://ec.europa.eu/research/index.cfm?lg=en&amp;pg=enquiries\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Research Enquiry Service</strong></span></a> &ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong><a href=\"http://een.ec.europa.eu/\" target=\"_blank\">Enterprise Europe Network</a> </strong></span>&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/api/contact/index.html\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>IT Helpdesk</strong></span></a><strong> </strong>- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Ethics</strong></span> &ndash; for compliance with ethical issues, see the <a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm\" target=\"_blank\">Online Manual</a> and <a href=\"http://ec.europa.eu/research/swafs/index.cfm?pg=policy&amp;lib=ethics\" target=\"_blank\">Science and Society Portal</a></p>\r\n<p><a href=\"http://www.iprhelpdesk.eu/\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>European IPR Helpdesk</strong></span></a> assists you on intellectual property issues</p>\r\n<p><a href=\"https://www.cencenelec.eu/research/Pages/default.aspx\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>CEN</strong></span><strong> <span style=\"color: rgb(0, 51, 102);\">and</span> </strong><span style=\"color: rgb(0, 51, 102);\"><strong>CENELEC</strong></span></a>, the <span style=\"color: rgb(0, 51, 102);\"><strong>European Standards Organisations</strong></span>, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at <span style=\"color: rgb(0, 0, 255);\">research@cencenelec.eu</span></p>\r\n<p><a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>The European Charter for Researchers and the Code of Conduct for their recruitment</strong></span></a></p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/grants/applying-for-funding/find-partners_en.htm\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Partner Search Services</strong></span></a> help you find a partner organisation for your proposal.</p>\r\n<p><a href=\"https://www.imi.europa.eu/about-imi/governance/states-representatives-group\" target=\"_blank\"><strong>IMI2 States Representative Group (SRG)</strong></a><strong> &ndash; contact you SRG member for assistance.</strong></p>\r\n<p><a href=\"mailto:applicants@imi.europa.eu?subject=Info%20request%20about%20IMI2%20JU%20Call%2015%20Topic%20xx\" target=\"_blank\"><strong>IMI2 JU Applicants Helpdesk</strong></a><strong> &ndash; contact the IMI2 Programme Office</strong></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Sumission Service, please click on the submission-button next to the type of action that corresponds to your proposal. You will then be asked to confirm your choice of the type of action and topic, as these cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [{"callId": 52392626119, "id": 165914291, "title": "IMI2 Call 15 stage 1 - Flash Call Info Report ", "sectionId": 52392626119, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 225756, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/h2020/imi2-2018-15-04/1840130-imi2_call_15_-_flash_call_info_report_-_stage_1_en.pdf", "id": 1840130, "fileName": "IMI2 Call 15 - Flash Call Info report - stage 1_EN.pdf", "common": false, "crc32": 1619582921}]}, {"callId": 52392626119, "id": 165914292, "title": "IMI2 Call 15 stage 2 - Flash Call Info Report ", "sectionId": 52392626119, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 223919, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/h2020/imi2-2018-15-04/1865115-imi2_call_15_-_flash_call_info_report_-_stage_2_en.pdf", "id": 1865115, "fileName": "IMI2 Call 15 - Flash Call Info report - stage 2_EN.pdf", "common": false, "crc32": 4002848585}]}], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Jul 16, 2019 4:28:44 PM", "lastChangeDate": "Jul 16, 2019 4:28:44 PM", "content": "<p>An overview of the evaluation results (<a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2018-15-02/1865115-imi2_call_15_-_flash_call_info_report_-_stage_2_en.pdf\" target=\"_blank\">flash call info &ndash; IMI2 Call 15 &ndash; second stage</a>) is now available under the call &lsquo;Additional documents&rsquo; tab</p>"}, {"approvalDate": "Jan 9, 2019 2:37:43 PM", "lastChangeDate": "Jan 9, 2019 2:37:43 PM", "content": "<p class=\"MsoNormal\">\r\n<p class=\"MsoNormal\">An overview of the evaluation results (<a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2018-15-01/1840130-imi2_call_15_-_flash_call_info_report_-_stage_1_en.pdf\" target=\"_blank\">flash call info &ndash; IMI2 Call 15 &ndash; first stage</a>) is now available under the call &lsquo;Additional documents&rsquo; tab<o:p></o:p></p>\r\n</p>"}, {"approvalDate": "Oct 25, 2018 11:36:31 AM", "lastChangeDate": "Oct 25, 2018 11:36:31 AM", "content": "<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">Proposal numbers</span></b><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">Stage 1 submission deadline for the Call<b> IMI2-2018-15-two-stage </b>has closed on the <b>24 October 2018.</b><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">42 proposals have been submitted.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">The breakdown per topic is:<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-01: &nbsp;&nbsp;2<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-02:&nbsp;15<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-03:&nbsp; &nbsp;3<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-04:&nbsp;&nbsp; 2<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-05: &nbsp;&nbsp;8<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">IMI2-2018-15-06:&nbsp;&nbsp; 6<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">IMI2-2018-15-07:&nbsp;&nbsp; 3<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">IMI2-2018-15-08:&nbsp;&nbsp; 3<o:p></o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:&#10;EN-IE;mso-fareast-language:EN-IE;mso-bidi-language:AR-SA\">Evaluation results for stage 1 are expected to be communicated in January 2019.</span></p>"}, {"approvalDate": "Jul 18, 2018 12:30:00 AM", "lastChangeDate": "Jul 18, 2018 12:30:00 AM", "content": "The submission session is now available for: IMI2-2018-15-01(IMI2-RIA), IMI2-2018-15-03(IMI2-RIA), IMI2-2018-15-02(IMI2-RIA), IMI2-2018-15-07(IMI2-RIA), IMI2-2018-15-08(IMI2-RIA), IMI2-2018-15-05(IMI2-RIA), IMI2-2018-15-04(IMI2-RIA), IMI2-2018-15-06(IMI2-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}